The estimated Net Worth of Brian M Culley is at least $2.25 Million dollars as of 24 May 2024. Mr Culley owns over 10,000 units of Lineage Cell Therapeutics Inc stock worth over $133,969 and over the last 6 years he sold LCTX stock worth over $1,291,500. In addition, he makes $828,350 as CEO und Pres & Director at Lineage Cell Therapeutics Inc.
Sign up
Mr A LCTX stock SEC Form 4 insiders trading
Mr has made over 19 trades of the Lineage Cell Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of LCTX stock worth $10,500 on 24 May 2024.
The largest trade he's ever made was selling 450,000 units of Lineage Cell Therapeutics Inc stock on 28 June 2021 worth over $1,291,500. On average, Mr trades about 33,442 units every 76 days since 2018. As of 24 May 2024 he still owns at least 154,842 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Mr Culley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Brian M. Culley M.A., M.B.A. biography
Brian M. Culley M.A., M.B.A. is the CEO, Pres & Director at Lineage Cell Therapeutics Inc.
What is the salary of Mr A?
As the CEO und Pres & Director of Lineage Cell Therapeutics Inc, the total compensation of Mr A at Lineage Cell Therapeutics Inc is $828,350. There are 1 executives at Lineage Cell Therapeutics Inc getting paid more, with Brandi Roberts having the highest compensation of $947,963.
How old is Mr A?
Mr A is 50, he's been the CEO und Pres & Director of Lineage Cell Therapeutics Inc since . There are 11 older and 4 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.
What's Mr A's mailing address?
Brian's mailing address filed with the SEC is 2173 SALK AVENUE,, SUITE 200, CARLSBAD, CA, 92008.
Insiders trading at Lineage Cell Therapeutics Inc
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley und Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.
What does Lineage Cell Therapeutics Inc do?
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
What does Lineage Cell Therapeutics Inc's logo look like?
Complete history of Mr Culley stock trades at Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc executives and stock owners
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brandi Roberts,
Chief Financial Officer -
Brian M. Culley M.A., M.B.A.,
CEO, Pres & Director -
Brian Culley,
Chief Executive Officer, Director -
Chase Leavitt,
General Counsel and Corporate Secretary -
Brandi L. Roberts,
Consultant -
Angus Russell,
Independent Director -
Michael Mulroy,
Independent Director -
Stephen Farrell,
Independent Director -
Neal Bradsher,
Independent Director -
Don Bailey,
Independent Director -
Deborah Andrews,
Independent Director -
Gary Hogge,
Senior Vice President of Clinical & Medical Affairs -
Alfred Kingsley,
Chairman of the Board -
Alexandra Hernandez,
Sr. Director of Fin. & Controller -
Dr. Rami Skaliter,
Chief Exec. Officer of Cell Cure Neurosciences Ltd. -
William Annett,
Pres & CEO of OncoCyte Corp. -
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
Sr. VP of Clinical & Medical Affairs -
Dr. François Binette M.Sc., Ph.D.,
Sr. VP & Global Head of R&D -
George A. Samuel III, J.D.,
Gen. Counsel & Company Sec. -
Ioana C. Hone,
Director of Investor Relations -
Kevin L. Cook,
Chief Financial Officer -
George A. Iii Samuel,
General Counsel/Secretary -
Anula Jayasuriya,
-
Dipti Amin,
-
Neal C Bradsher,
Director -
Alexandra Hernandez,
Sr Director Finance/Controller -
Kevin Leon Cook,
Chief Financial Officer -
Jill Ann Howe,
Chief Financial Officer